LFMD Strangle Strategy
LFMD (LifeMD, Inc.), in the Healthcare sector, (Medical - Pharmaceuticals industry), listed on NASDAQ.
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
LFMD (LifeMD, Inc.) trades in the Healthcare sector, specifically Medical - Pharmaceuticals, with a market capitalization of approximately $219.6M, a beta of 2.02 versus the broader market, a 52-week range of 2.56-15.84, average daily share volume of 1.3M, a public-listing history dating back to 2008, approximately 304 full-time employees. These structural characteristics shape how LFMD stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.02 indicates LFMD has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on LFMD?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current LFMD snapshot
As of May 15, 2026, spot at $4.37, ATM IV 83.70%, IV rank 35.13%, expected move 24.00%. The strangle on LFMD below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on LFMD specifically: LFMD IV at 83.70% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 24.00% (roughly $1.05 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LFMD expiries trade a higher absolute premium for lower per-day decay. Position sizing on LFMD should anchor to the underlying notional of $4.37 per share and to the trader's directional view on LFMD stock.
LFMD strangle setup
The LFMD strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LFMD near $4.37, the first option leg uses a $4.59 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LFMD chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LFMD shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $4.59 | N/A |
| Buy 1 | Put | $4.15 | N/A |
LFMD strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
LFMD strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on LFMD. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on LFMD
Strangles on LFMD are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the LFMD chain.
LFMD thesis for this strangle
The market-implied 1-standard-deviation range for LFMD extends from approximately $3.32 on the downside to $5.42 on the upside. A LFMD long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current LFMD IV rank near 35.13% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on LFMD should anchor more to the directional view and the expected-move geometry. As a Healthcare name, LFMD options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LFMD-specific events.
LFMD strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LFMD positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LFMD alongside the broader basket even when LFMD-specific fundamentals are unchanged. Always rebuild the position from current LFMD chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on LFMD?
- A strangle on LFMD is the strangle strategy applied to LFMD (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With LFMD stock trading near $4.37, the strikes shown on this page are snapped to the nearest listed LFMD chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LFMD strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the LFMD strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 83.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LFMD strangle?
- The breakeven for the LFMD strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LFMD market-implied 1-standard-deviation expected move is approximately 24.00%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on LFMD?
- Strangles on LFMD are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the LFMD chain.
- How does current LFMD implied volatility affect this strangle?
- LFMD ATM IV is at 83.70% with IV rank near 35.13%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.